Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1Anus Neoplasms 1

Interventions

Fluorouracil 26Radiotherapy 18Mitomycin 17Cisplatin 12Capecitabine 12pembrolizumab 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9Radiation 8Paclitaxel 8Biopsy 8fludarabine 7Specimen Handling 7Nivolumab 7Drug Therapy 7Carboplatin 7Surveys and Questionnaires 6Cetuximab 6Papillomavirus Vaccines 5dehydroftorafur 4aldesleukin 4Vaccines 4Radiotherapy, Intensity-Modulated 4Observation 4Irinotecan 4Watchful Waiting 3Taxes 3Oxaliplatin 3Light Coagulation 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Anus Neoplasms × ON 01910 × Gastrointestinal × Clear all
NCT01807546 2017-06-26

Oral Rigosertib for Squamous Cell Carcinoma

Traws Pharma, Inc.

Phase 2 Completed
64 enrolled
GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Anus Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡